Israel Englander’s Ocular Therapeutix OCUL Stock Holding History

Israel Englander’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-70,000	Closed	-$850K	–	6175
2025 Q4	$850K	Buy	+70,000	New	+$850K	﹤0.01%	4594

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Israel Englander's OCUL Position: Q2 2026 in Review

Israel Englander sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 34,006 shares — an estimated $288K sold.

Israel Englander first reported a position in OCUL in Q3 2014 and held it in 31 quarters. The position peaked at $45.1M in Q3 2025. 260 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Israel Englander reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
Israel Englander sold 34,006 Ocular Therapeutix shares in Q2 2026, an estimated $288K.
Israel Englander first reported a position in Ocular Therapeutix in Q3 2014 and held it in 31 quarters.
Israel Englander's Ocular Therapeutix position peaked at $45.1M in Q3 2025.
260 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.